Jazz Pharmaceuticals (JAZZ) SVP granted 10,116 shares after performance vest

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc executive Mary Elizabeth Henderson reported an equity award vesting. On January 16, 2026, she acquired 10,116 ordinary shares of Jazz Pharmaceuticals at a stated price of $0.0 per share. These shares relate to performance share awards originally granted on March 3, 2023, with the performance-based vesting conditions certified as achieved on January 16, 2026.

Following this transaction, Henderson beneficially owns 29,624 ordinary shares in total, held directly. She serves as SVP, Technical Operations at Jazz Pharmaceuticals. The Form 4 indicates this is a non-derivative acquisition tied to prior performance awards rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Henderson Mary Elizabeth

Role SVP, Technical Operations

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	10,116	$0.00	--

Holdings After Transaction: Ordinary Shares — 29,624 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Henderson Mary Elizabeth

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4 L2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Technical Operations

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	01/16/2026		A(1)		10,116	A	$0.0	29,624	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents ordinary shares of the Issuer that will be delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2023. The performance-based vesting requirements applicable to such awards were satisfied on January 16, 2026, which represents the date on which the level of performance attained was certified.

	By: /s/Paz Dizon as attorney in fact For: Mary Elizabeth Henderson	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider involved in this Jazz Pharmaceuticals (JAZZ) Form 4 filing?

The insider is Mary Elizabeth Henderson, who serves as SVP, Technical Operations at Jazz Pharmaceuticals plc.

What transaction did Mary Elizabeth Henderson report in this JAZZ Form 4?

She reported acquiring 10,116 ordinary shares of Jazz Pharmaceuticals on January 16, 2026, coded as an A (acquisition) in the non-derivative securities table.

How did Mary Elizabeth Henderson receive the 10,116 Jazz Pharmaceuticals shares?

According to the footnote, the 10,116 ordinary shares will be delivered under performance share awards granted on March 3, 2023, after performance-based vesting requirements were satisfied and certified on January 16, 2026.

What is Mary Elizabeth Henderson’s total Jazz Pharmaceuticals share ownership after the reported transaction?

After the transaction, she beneficially owns 29,624 ordinary shares of Jazz Pharmaceuticals, held in direct ownership.

Was this Jazz Pharmaceuticals (JAZZ) Form 4 transaction a market purchase?

No. The filing describes the shares as being delivered pursuant to performance share awards, with a stated transaction price of $0.0 per share, rather than an open-market purchase.

Does this Jazz Pharmaceuticals Form 4 involve any derivative securities?

No derivative securities are reported as acquired or disposed of in the provided portion of Table II; the disclosed activity concerns non-derivative ordinary shares only.